Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade N/A
- Symbol (TYME)
- Company Tyme Technologies, Inc.
- Price $0.31
- Changes Percentage (8.07%)
- Change $0.02
- Day Low $0.29
- Day High $0.32
- Year High $0.00
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2022
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.14
- Trailing P/E Ratio -2.2678832116788
- Forward P/E Ratio -2.2678832116788
- P/E Growth -2.2678832116788
- Net Income $-21,668,267
Income Statement
Quarterly
Annual
Latest News of TYME
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
SonsOfLibertyMedia.com Wins "Best Justice" Video & "Best News & Journalism Mini-Documentaries" Awards In Face Of Self-Appointed, Bought-And-Paid-For "Fact Checkers" (Video)
SonsOfLibertyMedia.com wins awards for best justice video and news & journalism mini-documentaries, despite opposition from "fact checkers." The site focuses on spreading God's word and addressing cur...
By The Washington Standard | 2 months ago
Continue with
Google
Continue with Apple